|
1
|
Lucas R and Keisari Y: Innovative cancer
treatments that augment radiotherapy or chemo-therapy by the use of
immunotherapy or gene therapy. Recent Pat Anticancer Drug Discov.
1:201–208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herbst RS: Review of epidermal growth
factor receptor biology. Int J Radiat Oncol Biol Phys. 59 Suppl
2:S21–S26. 2004. View Article : Google Scholar
|
|
3
|
Zhang H, Berezov A, Wang Q, Zhang G,
Drebin J, Murali R and Greene MI: ErbB receptors: From oncogenes to
targeted cancer therapies. J Clin Invest. 117:2051–2058. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Agelaki S and Georgoulias V: Epidermal
growth factor receptor inhibitors in the treatment of non-small
cell lung cancer. Expert Opin Emerg Drugs. 10:855–874. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arena S, Bellosillo B, Siravegna G,
Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S,
González I, et al: Emergence of multiple EGFR extracellular
mutations during cetuximab treatment in colorectal cancer. Clin
Cancer Res. 21:2157–2166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Montagut C, Dalmases A, Bellosillo B,
Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S,
Tsai SP, et al: Identification of a mutation in the extracellular
domain of the epidermal growth factor receptor conferring cetuximab
resistance in colorectal cancer. Nat Med. 18:221–223. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pier GB, Boyer D, Preston M, Coleman FT,
Llosa N, Mueschenborn-Koglin S, Theilacker C, Goldenberg H, Uchin
J, Priebe GP, et al: Human monoclonal antibodies to Pseudomonas
aeruginosa alginate that protect against infection by both mucoid
and nonmucoid strains. J Immunol. 173:5671–5678. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yates SP, Taylor PL, Jørgensen R, Ferraris
D, Zhang J, Andersen GR and Merrill AR: Structure-function analysis
of water-soluble inhibitors of the catalytic domain of exotoxin A
from Pseudomonas aeruginosa. Biochem J. 385:667–675. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barth S, Huhn M, Matthey B, Schnell R,
Tawadros S, Schinköthe T, Lorenzen J, Diehl V and Engert A:
Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates
successful elimination of disseminated human Hodgkin lymphoma in
SCID mice. Int J Cancer. 86:718–724. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hashimi SM, Yu S, Alqurashi N, Ipe DS and
Wei MQ: Immunotoxin-mediated targeting of claudin-4 inhibits the
proliferation of cancer cells. Int J Oncol. 42:1911–1918. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wolf P and Elsasser-Beile U: Pseudomonas
exotoxin A: From virulence factor to anti-cancer agent. Int J Med
Microbiol. 299:161–176. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Phelan MC: Basic techniques in mammalian
cell tissue culture. Curr Protoc Cell Biol Chapter. 1:Unit 1.1.
2007.
|
|
13
|
Bruell D, Stöcker M, Huhn M, Redding N,
Küpper M, Schumacher P, Paetz A, Bruns CJ, Haisma HJ, Fischer R, et
al: The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA'
suppresses growth of a highly metastatic pancreatic carcinoma cell
line. Int J Oncol. 23:1179–1186. 2003.PubMed/NCBI
|
|
14
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scaltriti M and Baselga J: The epidermal
growth factor receptor pathway: A model for targeted therapy. Clin
Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Michalska M and Wolf P: Pseudomonas
Exotoxin A: Optimized by evolution for effective killing. Front
Microbiol. 6:9632015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kwok TT and Sutherland RM: Differences in
EGF related radiosensitisation of human squamous carcinoma cells
with high and low numbers of EGF receptors. Br J Cancer.
64:251–254. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harari PM: Epidermal growth factor
receptor inhibition strategies in oncology. Endocr Relat Cancer.
11:689–708. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kuan CT, Wikstrand CJ and Bigner DD: EGF
mutant receptor vIII as a molecular target in cancer therapy.
Endocrine-Related Cancer. 8:83–96. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carpenter G and Cohen S: Epidermal growth
factor. J Biol Chem. 265:7709–7712. 1990.PubMed/NCBI
|
|
21
|
Schmidt M, Vakalopoulou E, Schneider DW
and Wels W: Construction and functional characterization of
scFv(14E1)-ETA-a novel, highly potent antibody-toxin specific for
the EGF receptor. Br J Cancer. 75:1575–1584. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chandler LA, Sosnowski BA, McDonald JR,
Price JE, Aukerman SL, Baird A, Pierce GF and Houston LL: Targeting
tumor cells via EGF receptors: Selective toxicity of an HBEGF-toxin
fusion protein. Int J Cancer. 78:106–111. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang X, Kessler E, Su LJ, Thorburn A,
Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, et
al: Diphtheria toxin-epidermal growth factor fusion protein
DAB389EGF for the treatment of bladder cancer. Clin Cancer Res.
19:148–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu TF, Hall PD, Cohen KA, Willingham MC,
Cai J, Thorburn A and Frankel AE: Interstitial diphtheria
toxin-epidermal growth factor fusion protein therapy produces
regressions of subcutaneous human glioblastoma multiforme tumors in
athymic nude mice. Clin Cancer Res. 11:329–334. 2005.PubMed/NCBI
|
|
25
|
Cree IA and Charlton P: Molecular chess?
Hallmarks of anti-cancer drug resistance. BMC Cancer. 17:102017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pao W, Wang TY, Riely GJ, Miller VA, Pan
Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE:
KRAS mutations and primary resistance of lung
adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e172005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shea M, Costa DB and Rangachari D:
Management of advanced non-small cell lung cancers with known
mutations or rearrangements: Latest evidence and treatment
approaches. Ther Adv Respir Dis. 10:113–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
